Literature DB >> 10073328

Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects.

Y N Wong1, S P King, D Simcoe, S Gorman, W Laughton, G C McCormick, P Grebow.   

Abstract

An open-label, single-center, single-dose, parallel-group study was performed in healthy young males and females as well as healthy elderly males to examine the influence of age and gender on the pharmacokinetics of modafinil following administration of a single 200 mg oral dose. Twelve subjects were enrolled in each of the following three groups: young males, young females, and elderly males. Each fasted (overnight) subject received 2 x 100 mg modafinil tablets. Blood and urine samples were collected at various times up to 72 hours postdose for the determination of plasma and urine levels of modafinil as well as the acid and sulfone metabolites. The plasma concentrations of the individual isomers, d- and l-modafinil, were also determined. Pharmacokinetic parameters were determined by noncompartmental methods. Modafinil was well tolerated at a single oral dose of 200 mg. The most commonly reported adverse events were headache, fever, pharyngitis, and asthenia. There were no clinically meaningful differences with respect to the incidence rate of treatment-emergent adverse events among the young female, young male, and old male groups. Modafinil was rapidly absorbed after oral dosing and slowly cleared (t1/2 approximately 11-14 hr) from the body. Modafinil acid was the major urinary metabolite, which accounted for 35% to 60% of the dose. Results from this study indicated that there were age and gender effects on modafinil clearance processes. In this regard, the clearance rate of modafinil in males decreased with age while young females cleared modafinil at a faster rate than young males. Stereospecific pharmacokinetics of modafinil were also demonstrated. The d-modafinil was eliminated three times faster than the l-modafinil.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10073328

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  34 in total

1.  A phase 3, double-blind, randomized, placebo-controlled study of armodafinil for excessive sleepiness associated with jet lag disorder.

Authors:  Russell P Rosenberg; Richard K Bogan; Jane M Tiller; Ronghua Yang; James M Youakim; Craig Q Earl; Thomas Roth
Journal:  Mayo Clin Proc       Date:  2010-06-07       Impact factor: 7.616

2.  Systemic exposure to armodafinil and its tolerability in healthy elderly versus young men: an open-label, multiple-dose, parallel-group study.

Authors:  Mona Darwish; Mary Kirby; Edward T Hellriegel; Ronghua Yang; Philmore Robertson
Journal:  Drugs Aging       Date:  2011-02-01       Impact factor: 3.923

3.  The Novel Modafinil Analog, JJC8-016, as a Potential Cocaine Abuse Pharmacotherapeutic.

Authors:  Hai-Ying Zhang; Guo-Hua Bi; Hong-Ju Yang; Yi He; Gilbert Xue; Jiajing Cao; Gianluigi Tanda; Eliot L Gardner; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neuropsychopharmacology       Date:  2017-03-07       Impact factor: 7.853

4.  Effects of modafinil and methylphenidate on visual attention capacity: a TVA-based study.

Authors:  Kathrin Finke; Chris M Dodds; Peter Bublak; Ralf Regenthal; Frank Baumann; Tom Manly; Ulrich Müller
Journal:  Psychopharmacology (Berl)       Date:  2010-03-30       Impact factor: 4.530

5.  Effects of modafinil on vestibular function during 24 hour sleep deprivation.

Authors:  Hao Zhan; Sujiang Xie; Hongbo Jia; Sihuang Wei; Baisheng Jing
Journal:  Front Med China       Date:  2007-05

6.  Acute modafinil exposure reduces daytime sleepiness in abstinent methamphetamine-dependent volunteers.

Authors:  James J Mahoney; Brian J Jackson; Ari D Kalechstein; Richard De La Garza; Lee C Chang; Thomas F Newton
Journal:  Int J Neuropsychopharmacol       Date:  2012-01-04       Impact factor: 5.176

Review 7.  Clinical pharmacokinetic profile of modafinil.

Authors:  Philmore Robertson; Edward T Hellriegel
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Armodafinil in the treatment of sleep/wake disorders.

Authors:  Jonathan R L Schwartz; Thomas Roth; Chris Drake
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

9.  Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.

Authors:  Mona Darwish; Mary Kirby; Philmore Robertson; Edward T Hellriegel
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

10.  Modafinil in the treatment of excessive sleepiness.

Authors:  Jonathan R L Schwartz
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.